Endometrial Cancer Screening in High-risk Populations

Sponsored by Peking University People's Hospital

About this trial

Last updated 3 years ago

Study ID

Endometrial cancer screening

Status

Unknown

Type

Interventional

Phase

N/A

Placebo

Accepting

18+ Years

Female

Trial Timing

Ended 5 months ago

What is this trial about?

Endometrial cancer is one of the most common malignancies of the reproductive system. The incidence of endometrial cancer has increased in recent years. No effective, low-cost screening method for populations at high risk exists. The traditional methods of endometrial cancer screening and diagnosis (segmented scraping and hysteroscopic biopsy) are invasive examinations with high medical costs. It is urgent to establish a reasonable, effective, economical, and non-invasive endometrial cancer screening strategy. This study aims to evaluate the effectiveness and feasibility of transvaginal ultrasound and microscale endometrial sampling biopsy in screening for endometrial precancerous lesions and endometrial cancer among high-risk populations in China, and to conduct cost-effectiveness analysis of different screening strategy, ultimately guiding the development of screening strategies that are suitable for high-risk populations in China.

What are the participation requirements?

Inclusion Criteria

1. Age ≥ 45 years old

2. Hypertension

3. Diabetes

4. Obesity (BMI ≥ 28)

5. History of estrogen application without progesterone antagonism

6. Polycystic ovary syndrome

7. Functional ovarian tumors (ovarian tumors that secrete estrogen) before surgical treatment

8. Infertility

9. During tamoxifen treatment, long-term use of mifepristone (greater than 3 months)

10. Abnormal uterine bleeding or vaginal discharge

11. Postmenopausal vaginal bleeding or vaginal discharge

12. Hereditary non polyposis colorectal cancer (HNPCC) patients over 35 years old, or patients with a family history of colorectal cancer or endometrial cancer

13. Cervical cytology examination indicates atypical glandular cells (AGC)

14. Previous history of ovarian cancer or breast cancer

Exclusion Criteria

1. Body temperature ≥ 37.5 ℃

2. Acute and subacute reproductive tract inflammation

3. Suspected pregnancy

4. Clearly diagnosed patients with malignant tumors of the reproductive tract

5. Acute severe systemic disease